STUDY SEARCH RESULTS

1 study found for your search request:  8591A-051

A Switch to Doravirine/Islatravir (DOR/ISL) in Participants with Human Immunodeficiency Virus Type 1...
Condition: HIV-1 Infection
Minimum Age: 18 years, Maximum Age: N/A
Gender: All
Study ID: NCT05631093
Status: Active, not recruiting




Copyright © 2025 · Merck & Co., Inc., Rahway, NJ, USA, and its affiliates. All rights reserved. · This site is intended only for residents of the United States.
Cookie Preferences  Privacy  Terms of Use  Consumer Health Data Privacy Policy  Your Privacy Choices   Accessibility  U.S. Corporate Site